Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

birabresib (OTX015)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Merck (MSD)

Drug class:

BRD4 inhibitor, BRD2 inhibitor, BRD3 inhibitor

Related drugs:

MLL translocation	Acute Myelogenous Leukemia	MLL translocation	Acute Myelogenous Leukemia	OTX015 Resistant: C3 – Early Trials OTX015 Resistant : C3	OTX015 Resistant: C3 – Early Trials OTX015 Resistant : C3
SPI1 deletion	Acute Myelogenous Leukemia	SPI1 deletion	Acute Myelogenous Leukemia	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3
MTHFR underexpression	Acute Myelogenous Leukemia	MTHFR underexpression	Acute Myelogenous Leukemia	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D
TERT rearrangement	Neuroblastoma	TERT rearrangement	Neuroblastoma	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
MLL mutation	Acute Myelogenous Leukemia	MLL mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
ARID1A mutation	Bladder Cancer	ARID1A mutation	Bladder Cancer	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D
Chr inv(3)t(3;3) + MECOM overexpression	Acute Myelogenous Leukemia	Chr inv(3)t(3;3) + MECOM overexpression	Acute Myelogenous Leukemia	OTX015 + BC2059 Sensitive: D – Preclinical OTX015 + BC2059 Sensitive : D	OTX015 + BC2059 Sensitive: D – Preclinical OTX015 + BC2059 Sensitive : D
FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	OTX015 + FHD-286 Sensitive: D – Preclinical OTX015 + FHD-286 Sensitive : D	OTX015 + FHD-286 Sensitive: D – Preclinical OTX015 + FHD-286 Sensitive : D